Seite - (000326) - in Biomedical Chemistry: Current Trends and Developments

in drug design. Bioorganic & Medicinal Chemistry Letters, 4(14), 1679-1684. Boden, P., Eden, J. M., Hodgson, et al. (1995). The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonists. Bioorganic & Medicinal Chemistry Letters, 5(16), 1773-1778. Botros, M., Hallberg, M., Johansson, T., et al. (2006). Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP1-7 in the rat spinal cord. Peptides, 27(4), 753-759. Brandsch, M. (2009). Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opinion on Drug Metabolism & Toxicology, 5(8), 887-905. Brodin, B., Nielsen, C. U., Steffansen, et al. (2002). Transport of peptidomimetic drugs by the intestinal di/tri-peptide transporter, PepT1. Pharmacology & Toxicology, 90(6), 285-296. Carlsson, A., Ohsawa, M., Hallberg, et al. (2010). Substance P1-7 induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors. European Journal of Pharmacology, 626(2-3), 250-255. Chang, M. M., Leeman, S. E., & Niall, H. D. (1971). Amino-Acid Sequence of Substance P. Nature- New Biology, 232(29), 86-87. Claerhout, S., Sharma, S., Sköld, C. et al. (2012). Synthesis of functionalized furopyrazines as restricted dipeptidomimetics. Tetrahedron, 68(14), 3019-3029. Culman, J., & Unger, T. (1995). Central Tachykinins - Mediators of Defense Reaction and Stress Reactions. Canadian Journal of Physiology and Pharmacology, 73(7), 885-891. De Araujo, J. E., Huston, J. P., & Brandao, M. L. (2001). Opposite effects of substance P fragments C (anxiogenic) and N (anxiolytic) injected into dorsal periaqueductal gray. European Journal of Pharmacology, 432(1), 43-51. Ebner, K., Muigg, P., Singewald, G., et al. (2008). Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Annals of the New York Academy of Sciences, 1144(Neural Signaling Opportunities for Novel Diagnostic Approaches and Therapies), 61-73. Erspamer, V. (1981). The tachykinin peptide family. Trends in NeuroSciences, 4(11), 267-269. Fichna, J., Janecka, A., Costentin, et al. (2007). The endomorphin system and its evolving neurophysiological role. Pharmacological Reviews, 59(1), 88-123. Fransson, R., Botros, M., Nyberg, F., et al. (2008). Small peptides mimicking substance P (1-7) and encompassing a C-terminal amide functionality. Neuropeptides, 42(1), 31-37. Fransson, R., Botros, M., Sköld, C., et al. (2010a). Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. Journal of Medicinal Chemistry, 53(6), 2383- 2389. Fransson, R., Carlsson, A., Sköld, et al. (2010b). Design and Synthesis of Small Substance P (1-7) Mimetics. Paper presented at the INRC 2010, Malmö, Sweden. Fransson, R., Sköld, C., Kratz, J. M., et al. (2013). Constrained H-Phe-Phe-NH2 Analogues with High Affinity to the Substance P 1-7 Binding Site and with Improved Metabolic Stability and Cell Permeability. Journal of Medicinal Chemisrty, 56(12), 4953-4965. Giacomini, K. M., Huang, S. M., Tweedie, D. J., et al. (2010). Membrane transporters in drug development. Nature Reviews: Drug Discovery, 9(3), 215-236. Grauer, A., & Konig, B. (2009). Peptidomimetics - A Versatile Route to Biologically Active